Cyber Cloud Oncology
Open Access
- 25 August 2022
- journal article
- Published by IntechOpen in Digital Medicine and Healthcare Technology
- Vol. 2022, 1-18
- https://doi.org/10.5772/dmht.08
Abstract
Breast cancer treatment is experiencing a groundswell transformation directed by a better understanding of tumour cell metabolism. Observation of metabolic tumor cell variations led to precision medicine. In addition, a “new wave” of rapid drug development spurred by the 2016 U.S. government’s Moonshot program is in the backdrop and, in part, placed an overwhelming burden on clinical oncologists and patients. In 2016, the U.S. government announced the Cancer Moonshot intending to make ten years’ worth of progress in cancer prevention, diagnosis, and treatment in just five years. In the 5-year interval 2017–2021, the FDA issued an unprecedented 161 new approvals of therapeutic agents for various indications in adult patients with solid tumors. Cancer chemotherapy now involves a complex balance between new drug development, clinical trial observations, FDA drug approvals, next-generation sequencing of tumour and blood samples, and “consensus opinion” between medical, surgical, and radiation oncologists. New “precision” medicine selects precise treatment options that benefit patients based on the genomic makeup of their tumour. Genomic profiling provides information about a diagnosis and prognosis and often predicts response or resistance to therapy, years before routine imaging studies change. New technologies, including liquid biopsy and next-generation sequencing (NGS), have identified oncogenic drivers and unique drugs capable of targeting and inhibiting/modifying newly discovered oncogenic driver pathways. Herein is presented a helpful method for keeping track of and rapidly updating physicians on newly developed effective treatments and therapeutic consensus opinion, which often lacks contemporary harmonization between official oncology societies. Physicians and supporting healthcare workers contribute the most to patients when equipped with knowledge of the newest, least toxic, and most effective therapies.Keywords
This publication has 5 references indexed in Scilit:
- A Novel Risk-Scoring System to Identify the Potential Population Benefiting From Adjuvant Chemotherapy for Node-Negative TNBC Patients With Tumor Size Less Than 1 cmFrontiers in Oncology, 2022
- Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021Annals of Oncology, 2021
- Expert review on systemic treatment in the St. Gallen International Breast Cancer Conference 2021Translational Breast Cancer Research, 2021
- St. Gallen/Vienna 2021: A Brief Summary of the Consensus Discussion on Customizing Therapies for Women with Early Breast CancerBreast Care, 2021
- Discrepancies between ESMO and NCCN breast cancer guidelines: An appraisalThe Breast, 2015